Haematological Disease

Haematological Disease

Show other versions (1)

Patients with haematological diseases are major users of blood components. This chapter focuses on bone marrow failure syndromes and stem cell transplantation, in addition to haematological malignancies. The transfusion support of patients with haematological disease may be complex and includes the...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Estcourt, L, Stanworth, S, Murphy, M
Formato:	Book section
Publicado em:	John Wiley and Sons 2013

Registos relacionados

Haematological Disease
Por: Murphy, M, et al.
Publicado em: (2009)

Platelet transfusions for patients with haematological malignancies: who needs them?
Por: Estcourt, L, et al.
Publicado em: (2011)

Intracranial haemorrhage in thrombocytopenic haematology patients—a nested case–control study: the InCiTe study protocol
Por: Estcourt, L, et al.
Publicado em: (2014)

Intracranial hemorrhage in patients with haematological malignancy, a nested case-control study
Por: Estcourt, L, et al.
Publicado em: (2017)

Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders
Por: Estcourt, L, et al.
Publicado em: (2016)

Anti-fibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders (Protocol)
Por: Wardrop, D, et al.
Publicado em: (2016)

Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological malignancies (Review).
Por: Wardrop, D, et al.
Publicado em: (2013)

Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation
Por: Desborough, M, et al.
Publicado em: (2016)

Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
Por: Estcourt, L, et al.
Publicado em: (2012)

Different doses of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation
Por: Estcourt, L, et al.
Publicado em: (2014)

Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
Por: Estcourt, L, et al.
Publicado em: (2015)

Prophylactic platelet transfusions
Por: Estcourt, L, et al.
Publicado em: (2010)

Different platelet count thresholds to guide use of prophylactic platelet transfusions for patients with hematological disorders after myelosuppressive chemotherapy or stem cell transplantation
Por: Estcourt, L, et al.
Publicado em: (2016)

Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation (Review)
Por: Estcourt, L, et al.
Publicado em: (2015)

Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies- The ATHENA study
Por: Estcourt, L, et al.
Publicado em: (2014)

Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation (Protocol).
Por: Estcourt, L, et al.
Publicado em: (2014)

Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation (protocol)
Por: Estcourt, L, et al.
Publicado em: (2014)

Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies- the ATHENA study.
Por: Estcourt, L, et al.
Publicado em: (2014)

Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies‐ The ATHENA study
Por: Estcourt, L, et al.
Publicado em: (2014)

Feasibility and usefulness of self-assessment of bleeding in patients with haematological malignancies, and the association between platelet count and bleeding.
Por: Stanworth, S, et al.
Publicado em: (2006)

A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation (protocol)
Por: Estcourt, L, et al.
Publicado em: (2014)

Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: A subgroup analysis of a randomized trial (CME)
Por: Stanworth, S, et al.
Publicado em: (2014)

Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial.
Por: Stanworth, S, et al.
Publicado em: (2014)

2016 National audit of red cell use in adult haematology patients
Por: Karakantza, M, et al.
Publicado em: (2017)

A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
Por: Crighton, GL, et al.
Publicado em: (2015)

Pathogen-reduced platelets for the prevention of bleeding (protocol)
Por: Butler, C, et al.
Publicado em: (2011)

A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation (Russian Translation of Cochrane Plain Language Summary)
Por: Crighton, GL, et al.
Publicado em: (2021)

Pathogen-reduced platelets for the prevention of bleeding (Review)
Por: Estcourt, L, et al.
Publicado em: (2017)

Is sepsis a risk factor for bleeding in adults with hematologic malignancies?
Por: Estcourt, L, et al.
Publicado em: (2017)

Pathogen-reduced platelets for the prevention of bleeding (Review)
Por: Butler, C, et al.
Publicado em: (2013)

Pathogen-reduced platelets for the prevention of bleeding.
Por: Butler, C, et al.
Publicado em: (2013)

Transfusion practice and safety: current status and possibilities for improvement.
Por: Murphy, M, et al.
Publicado em: (2011)

Can you see the wood for the trees? Making sense of forest plots in systematic reviews 2. Analysis of the combined results from the included studies.
Por: Hyde, C, et al.
Publicado em: (2008)

Evidence for indications of fresh frozen plasma.
Por: Stanworth, S, et al.
Publicado em: (2007)

Can you see the wood for the trees? Making sense of forest plots in systematic reviews.
Por: Hyde, C, et al.
Publicado em: (2008)

Prophylactic platelet transfusions in patients with blood malignancies: Cost analysis of a randomized trial
Por: Campbell, H, et al.
Publicado em: (2014)

Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial.
Por: Campbell, H, et al.
Publicado em: (2014)

Platelet transfusions in haematology patients: are we using them appropriately?
Por: Estcourt, L, et al.
Publicado em: (2012)

Alternatives to allogeneic platelet transfusion
Por: Desborough, M, et al.
Publicado em: (2016)

Putting clinical trials into context.
Por: Hyde, C, et al.
Publicado em: (2005)